Here we reported that zanubrutinib overcame TOX2+ terminal Tex cells during both immune‐bridging and immune‐maintenance therapy, correlating with reduced abundance of tumour‐infiltrating PD‐1‐overexpressing terminal Tex cells and good response to CAR T‐cell therapy. This evidence concerns the gene PDCD1 and neoplasm.